The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

The Roctavian program was originally acquired from University College London and appears to have limited commercial potential due to ongoing reimbursement issues in the US and EU. BioMarin has ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

BioMarin Pharmaceutical is up 5.3% since the beginning of the year, but at $70 per share, it is still trading 25.4% below its 52-week high of $93.84 from August 2024.